BACKGROUND: As a result of effective combination antiretroviral therapy (cART) and advanced supportive healthcare, a growing number of human immunodeficiency virus (HIV)-infected children survive into adulthood. The period of transition to adult care is often associated with impaired adherence to treatment and discontinuity of care. We aimed to evaluate virological and social outcomes of HIV-infected adolescents and young adults (AYAs) before and after transition, and explore which factors are associated with virological failure. METHODS: We included 59 HIV-infected AYAs from the Netherlands who had entered into pediatric care and transitioned from pediatric to adult healthcare. We used HIV RNA load and cART data from the Dutch Stichting HIV Monitoring database (1996-2014), and collected social and treatment data from patients' medical records from all Dutch pediatric HIV treatment centers and 14 Dutch adult treatment centers involved. We evaluated risk factors for virological failure (VF) in a logistic regression model adjusted for repeated measurements. RESULTS: HIV VF occurred frequently during the study period (14%-36%). During the transition period (from 18 to 19 years of age) there was a significant increase in VF compared with the reference group of children aged 12-13 years (odds ratio, 4.26 [95% confidence interval, 1.12-16.28]; P = .03). Characteristics significantly associated with VF were low educational attainment and lack of autonomy regarding medication adherence at transition. CONCLUSIONS: HIV-infected AYAs are vulnerable to VF, especially during the transition period. Identification of HIV-infected adolescents at high risk for VF might help to improve treatment success in this group.
BACKGROUND: As a result of effective combination antiretroviral therapy (cART) and advanced supportive healthcare, a growing number of human immunodeficiency virus (HIV)-infectedchildren survive into adulthood. The period of transition to adult care is often associated with impaired adherence to treatment and discontinuity of care. We aimed to evaluate virological and social outcomes of HIV-infected adolescents and young adults (AYAs) before and after transition, and explore which factors are associated with virological failure. METHODS: We included 59 HIV-infected AYAs from the Netherlands who had entered into pediatric care and transitioned from pediatric to adult healthcare. We used HIV RNA load and cART data from the Dutch Stichting HIV Monitoring database (1996-2014), and collected social and treatment data from patients' medical records from all Dutch pediatric HIV treatment centers and 14 Dutch adult treatment centers involved. We evaluated risk factors for virological failure (VF) in a logistic regression model adjusted for repeated measurements. RESULTS:HIV VF occurred frequently during the study period (14%-36%). During the transition period (from 18 to 19 years of age) there was a significant increase in VF compared with the reference group of children aged 12-13 years (odds ratio, 4.26 [95% confidence interval, 1.12-16.28]; P = .03). Characteristics significantly associated with VF were low educational attainment and lack of autonomy regarding medication adherence at transition. CONCLUSIONS:HIV-infected AYAs are vulnerable to VF, especially during the transition period. Identification of HIV-infected adolescents at high risk for VF might help to improve treatment success in this group.
Authors: Brian C Zanoni; Moherndran Archary; Tamarra Subramony; Thobekile Sibaya; Christina Psaros; Jessica E Haberer Journal: AIDS Behav Date: 2021-01
Authors: Sophia A Hussen; Rana Chakraborty; Andrea Knezevic; Andres Camacho-Gonzalez; Eugene Huang; Rob Stephenson; Carlos Del Rio Journal: J Int AIDS Soc Date: 2017-09-01 Impact factor: 5.396
Authors: Ali Judd; Elizabeth Chappell; Anna Turkova; Sophie Le Coeur; Antoni Noguera-Julian; Tessa Goetghebuer; Katja Doerholt; Luisa Galli; Dasja Pajkrt; Laura Marques; Intira J Collins; Diana M Gibb; Maria Isabel González Tome; Marisa Navarro; Josiane Warszawski; Christoph Königs; Vana Spoulou; Filipa Prata; Elena Chiappini; Lars Naver; Carlo Giaquinto; Claire Thorne; Magdalena Marczynska; Liubov Okhonskaia; Klara Posfay-Barbe; Pradthana Ounchanum; Pornchai Techakunakorn; Galina Kiseleva; Ruslan Malyuta; Alla Volokha; Luminita Ene; Ruth Goodall Journal: PLoS Med Date: 2018-01-30 Impact factor: 11.069